Peptidomimetics are synthetic analogs that retain the essential structure and function of peptides but with chemical ...

ATLANTA and BOSTON, May 28, 2025 (GLOBE NEWSWIRE) -- ABLi Therapeutics ("ABLi”), a biotechnology company developing ...

DelveInsight’s Peritoneal Cancer Pipeline report depicts a robust space with 55+ active players working to develop 60+ ...

Agency supports primary and novel secondary and exploratory endpoints proposed for Phase 3 Trial(s) Opportunity to utilize ...

Dizal (SSE:688192), a biopharmaceutical company committed to developing novel medicines for the treatment of cancer and immunological diseases, announced today that it will present latest clinical ...

Discover 9 promising small molecule drug discovery companies that recently raised funding for their potentially breakthrough ...

Takeda is organized around five core businesses: oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for over 80% of revenue. It also has a developing ...

We have a session with Microbix to discuss the Q2 results they put out this morning. You can find those on the company's website on SEDAR and the press release probably was sent to your inbox. Let's ...

The molecular basis for this targeting remains unclear, but indicates that some sort of monoubiquitin receptor could be ... different kinases might phosphorylate FANCD2 near lysine 561 to activate ...

Considered the natural "hunger hormone," ghrelin could be the key to preventing debilitating chronic constipation experienced ...

As Australia faces a turning point in obesity management, researchers from Monash University have contributed new insights ...